Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this ...

Please provide your email address to receive an email when new articles are posted on . Dabigatran is an oral anticoagulant - a synthetic thrombin inhibitor – that is approved in the United States for ...

Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically ...

The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. In a randomized, ...

SILVER SPRING, Maryland — The US FDA is following in the footsteps of the European Medicines Agency (EMA) in warning that the anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) should not be ...

In two trials exploring potential new indications, dabigatran (Pradaxa; Boehringer Ingelheim) failed to show significant advantages over standard treatments for embolic stroke of undetermined source ...

Learn everything you need to know about Dabigatran-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The new findings, presented Sunday at the American Society of Hematology (ASH) 2009 Meeting and published online in the New England Journal of Medicine, come hard on the heels of the RE-LY results, ...

In patients with atrial fibrillation (AF), treatment with the direct thrombin inhibitor dabigatran etexilate is safe and effective at twice-daily doses of either 150 mg or 110 mg, report the ...

The availability of dabigatran 110 mg in the US may be a favorable therapeutic option for patients at high risk of bleeding, who may be willing to accept a higher probability of stroke for a reduced ...

Late Monday, the US Food and Drug Administration approved dabigatran (Pradaxa; Boehringer Ingelheim) for treating venous thromboembolism (VTE) in children younger than 12 years old (but older than 3 ...

Dabigatran etexilate (Pradaxa, Boehringer Ingelheim) is a direct inhibitor of the enzyme thrombin. Thrombin is a key enzyme in blood clot (thrombus) formation because it enables the conversion of ...